Weekly HIV Combo Lenacapavir/Islatravir Matches Daily Regimen at 48 Weeks

A study reports that a weekly oral combination of lenacapavir and islatravir maintains HIV viral suppression for 48 weeks, matching the efficacy of daily oral therapy. The finding, if confirmed in larger trials, could simplify HIV treatment adherence, though long-term durability and resistance profiles remain uncertain.